{"schema_version":"secwatch.filing_event.v1","accession":"0001171843-26-001299","form_type":"8-K","ticker":"ABUS","cik":"0001447028","company_name":"Arbutus Biopharma Corp","filed_at":"2026-03-03T23:59:59+00:00","discovered_at":"2026-05-14T18:02:35.104101+00:00","generated_at":"2026-05-15T22:12:50.989650+00:00","sec_items":["1.01","8.01","9.01"],"event_type":"litigation","sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"confidence":"high","headline":"Arbutus/Genevant settle Moderna LNP patent litigation for $2.25B; $950M upfront due July 2026","bullets":["Moderna to pay $950M upfront by July 8, 2026, plus $1.3B contingent on affirming rejection of Section 1498 defense.","Arbutus receives 20% of proceeds after litigation costs under its Genevant license; total potential $2.25B.","Arbutus evaluating a return of capital to shareholders in Q3 2026, tied to the upfront payment.","Settlement includes judgment of infringement and no invalidity on four patents; global license for SM-102 LNP mRNA vaccines."],"urls":{"canonical":"https://secwatch.observer/filing/0001171843-26-001299","json":"https://secwatch.observer/filing/0001171843-26-001299.json","markdown":"https://secwatch.observer/filing/0001171843-26-001299.md","text":"https://secwatch.observer/filing/0001171843-26-001299.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1447028/000117184326001299/0001171843-26-001299-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1447028/000117184326001299/f8k_030326.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T22:12:50.989650+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"8fc31b6220906dce47f4a406775c43f7bf172d2d","claim":"Arbutus Biopharma Corp entered into Settlement Agreement with Moderna, Inc. and ModernaTx, Inc. (together, Moderna) valued at $950.0 million noncontingent lump sum payment (effective 2026-03-03).","evidence_excerpt":"On March 3, 2026 (the “Effective Date”), Arbutus Biopharma Corporation (“Arbutus” or the “Company”), Genevant Sciences GmbH (“Genevant” and together with Arbutus, “Arbutus/Genevant”), and, solely for certain purposes, Genevant Sciences Ltd., and Moderna, Inc. and ModernaTx, Inc. (together, “Moderna”) entered into a settlement agreement (the “Settlement Agreement”) to resolve all patent infringement litigation between Arbutus/Genevant and Moderna pending in the U.S. and internationally relating to Moderna’s unauthorized use of Arbutus/Genevant’s lipid nanoparticle (“LNP”) delivery technology in its vaccines, including Spikevax® (the “LNP Litigation”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1447028/000117184326001299/0001171843-26-001299-index.htm","confidence":0.9}],"comparable_filings":[{"accession":"0001171843-26-002591","ticker":"AGAE","company_name":"Allied Gaming & Entertainment Inc.","filed_at":"2026-04-21T23:59:59+00:00","headline":"Allied Gaming settles litigation with Knighted for ~$5.94M paid over 3 months; CEO Li personally guarantees payment","event_type":"litigation","sec_items":["1.01","5.02","8.01","9.01"],"materiality_score":0.8,"calibrated_materiality_score":0.8,"match_reasons":["same fact type: material_agreement","same SEC item: 1.01, 8.01, 9.01","same event type: litigation","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001171843-26-002591","json":"https://secwatch.observer/filing/0001171843-26-002591.json","markdown":"https://secwatch.observer/filing/0001171843-26-002591.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1708341/000117184326002591/0001171843-26-002591-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1708341/000117184326002591/f8k_042026.htm"},"side_by_side_evidence":{"fact_type":"material_agreement","source_excerpt":"On March 3, 2026 (the “Effective Date”), Arbutus Biopharma Corporation (“Arbutus” or the “Company”), Genevant Sciences GmbH (“Genevant” and together with Arbutus, “Arbutus/Genevant”), and, solely for certain purposes, Genevant Sciences Ltd., and Moderna, Inc. and ModernaTx, Inc. (together, “Moderna”) entered into a settlement agreement (the “Settlement Agreement”) to resolve all patent infringement litigation between Arbutus/Genevant and Moderna pending in the U.S. and internationally relating to Moderna’s unauthorized use of Arbutus/Genevant’s lipid nanoparticle (“LNP”) delivery technology in its vaccines, including Spikevax® (the “LNP Litigation”).","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1447028/000117184326001299/0001171843-26-001299-index.htm","comparable_excerpt":"On April 10, 2026, Allied Gaming & Entertainment Inc. (the “Company”) and Yangyang Li, its Chief Executive Officer and Chairman, in his personal capacity (“Mr. Li”, and together with the Company, the “Allied Parties”) entered into a binding Term Sheet for Global Resolution (the “Term Sheet”) with Knighted Pastures, LLC (“Knighted”) and Roy Choi, in his personal capacity (“Mr. Choi”, and together with Knighted, the “Knighted Parties”).","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1708341/000117184326002591/0001171843-26-002591-index.htm"}},{"accession":"0001193125-26-094084","ticker":"TRNR","company_name":"Interactive Strength, Inc.","filed_at":"2026-03-05T23:59:59+00:00","headline":"TRNR recovers $6.4M in full settlement of Sportstech loan dispute, ends legal proceedings","event_type":"litigation","sec_items":["1.01","8.01","9.01"],"materiality_score":0.8,"calibrated_materiality_score":0.8,"match_reasons":["same fact type: material_agreement","same SEC item: 1.01, 8.01, 9.01","same event type: litigation","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-094084","json":"https://secwatch.observer/filing/0001193125-26-094084.json","markdown":"https://secwatch.observer/filing/0001193125-26-094084.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1785056/000119312526094084/0001193125-26-094084-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1785056/000119312526094084/trnr-20260227.htm"},"side_by_side_evidence":{"fact_type":"material_agreement","source_excerpt":"On March 3, 2026 (the “Effective Date”), Arbutus Biopharma Corporation (“Arbutus” or the “Company”), Genevant Sciences GmbH (“Genevant” and together with Arbutus, “Arbutus/Genevant”), and, solely for certain purposes, Genevant Sciences Ltd., and Moderna, Inc. and ModernaTx, Inc. (together, “Moderna”) entered into a settlement agreement (the “Settlement Agreement”) to resolve all patent infringement litigation between Arbutus/Genevant and Moderna pending in the U.S. and internationally relating to Moderna’s unauthorized use of Arbutus/Genevant’s lipid nanoparticle (“LNP”) delivery technology in its vaccines, including Spikevax® (the “LNP Litigation”).","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1447028/000117184326001299/0001171843-26-001299-index.htm","comparable_excerpt":"On February 27, 2026, the Company and Sportstech entered into a Settlement Agreement (the “Settlement Agreement”), pursuant to which Sportstech was to pay the Company $6,350,000 along with making a payment to the Company’s counsel in its legal dispute with Sportstech (the “Settlement Payment”).","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1785056/000119312526094084/0001193125-26-094084-index.htm"}},{"accession":"0001140361-26-007548","ticker":"ROIV","company_name":"Roivant Sciences Ltd.","filed_at":"2026-03-03T23:59:59+00:00","headline":"Roivant's Genevant/Arbutus settles Moderna LNP patent suit for $950M upfront, plus $1.3B contingent","event_type":"litigation","sec_items":["1.01","7.01","8.01","9.01"],"materiality_score":0.9,"calibrated_materiality_score":0.9,"match_reasons":["same fact type: material_agreement","same SEC item: 1.01, 8.01, 9.01","same event type: litigation","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-26-007548","json":"https://secwatch.observer/filing/0001140361-26-007548.json","markdown":"https://secwatch.observer/filing/0001140361-26-007548.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1635088/000114036126007548/0001140361-26-007548-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1635088/000114036126007548/ef20067067_8k.htm"},"side_by_side_evidence":{"fact_type":"material_agreement","source_excerpt":"On March 3, 2026 (the “Effective Date”), Arbutus Biopharma Corporation (“Arbutus” or the “Company”), Genevant Sciences GmbH (“Genevant” and together with Arbutus, “Arbutus/Genevant”), and, solely for certain purposes, Genevant Sciences Ltd., and Moderna, Inc. and ModernaTx, Inc. (together, “Moderna”) entered into a settlement agreement (the “Settlement Agreement”) to resolve all patent infringement litigation between Arbutus/Genevant and Moderna pending in the U.S. and internationally relating to Moderna’s unauthorized use of Arbutus/Genevant’s lipid nanoparticle (“LNP”) delivery technology in its vaccines, including Spikevax® (the “LNP Litigation”).","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1447028/000117184326001299/0001171843-26-001299-index.htm","comparable_excerpt":"On March 3, 2026 (the “Effective Date”), Genevant Sciences GmbH (“Genevant”), a subsidiary of Roivant Sciences Ltd. (the “Company” or “Roivant”), Arbutus Biopharma Corp. (together with Genevant, “Genevant/Arbutus”), and, solely for certain purposes, Genevant Sciences Ltd., and Moderna, Inc. and ModernaTx, Inc. (together, “Moderna”) entered into a settlement agreement (the “Settlement Agreement”)","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1635088/000114036126007548/0001140361-26-007548-index.htm"}},{"accession":"0001628280-26-027280","ticker":"OPY","company_name":"OPPENHEIMER HOLDINGS INC","filed_at":"2026-04-27T23:59:59+00:00","headline":"Oppenheimer settles cash-sweep class action for $70M, to impact Q1 earnings","event_type":"litigation","sec_items":["1.01","9.01"],"materiality_score":0.8,"calibrated_materiality_score":0.8,"match_reasons":["same fact type: material_agreement","same SEC item: 1.01, 9.01","same event type: litigation","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-26-027280","json":"https://secwatch.observer/filing/0001628280-26-027280.json","markdown":"https://secwatch.observer/filing/0001628280-26-027280.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/791963/000162828026027280/0001628280-26-027280-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/791963/000162828026027280/opy-20260424.htm"},"side_by_side_evidence":{"fact_type":"material_agreement","source_excerpt":"On March 3, 2026 (the “Effective Date”), Arbutus Biopharma Corporation (“Arbutus” or the “Company”), Genevant Sciences GmbH (“Genevant” and together with Arbutus, “Arbutus/Genevant”), and, solely for certain purposes, Genevant Sciences Ltd., and Moderna, Inc. and ModernaTx, Inc. (together, “Moderna”) entered into a settlement agreement (the “Settlement Agreement”) to resolve all patent infringement litigation between Arbutus/Genevant and Moderna pending in the U.S. and internationally relating to Moderna’s unauthorized use of Arbutus/Genevant’s lipid nanoparticle (“LNP”) delivery technology in its vaccines, including Spikevax® (the “LNP Litigation”).","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1447028/000117184326001299/0001171843-26-001299-index.htm","comparable_excerpt":"On April 24, 2026, Oppenheimer & Co., Inc. (“Oppenheimer”), the principal operating subsidiary of Oppenheimer Holdings Inc. (the “Company”), reached an agreement to settle the previously disclosed litigation styled Liberty Capital Group, Individually and on Behalf of All Others Similarly Situated v. Oppenheimer Holdings Inc., Oppenheimer & Co. Inc., and Oppenheimer Asset Management Inc. , No. 1:25-cv04822-JSR which was filed in the United States District Court for the Southern District of New York in June of 2025 (the “ District Court”).","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/791963/000162828026027280/0001628280-26-027280-index.htm"}},{"accession":"0001682852-26-000047","ticker":"MRNA","company_name":"Moderna, Inc.","filed_at":"2026-03-05T23:59:59+00:00","headline":"Moderna settles all patent litigation with Arbutus/Genevant for $950M upfront, up to $1.3B contingent","event_type":"litigation","sec_items":["1.01"],"materiality_score":0.85,"calibrated_materiality_score":0.85,"match_reasons":["same fact type: material_agreement","same SEC item: 1.01","same event type: litigation","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001682852-26-000047","json":"https://secwatch.observer/filing/0001682852-26-000047.json","markdown":"https://secwatch.observer/filing/0001682852-26-000047.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1682852/000168285226000047/0001682852-26-000047-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1682852/000168285226000047/mrna-20260303.htm"},"side_by_side_evidence":{"fact_type":"material_agreement","source_excerpt":"On March 3, 2026 (the “Effective Date”), Arbutus Biopharma Corporation (“Arbutus” or the “Company”), Genevant Sciences GmbH (“Genevant” and together with Arbutus, “Arbutus/Genevant”), and, solely for certain purposes, Genevant Sciences Ltd., and Moderna, Inc. and ModernaTx, Inc. (together, “Moderna”) entered into a settlement agreement (the “Settlement Agreement”) to resolve all patent infringement litigation between Arbutus/Genevant and Moderna pending in the U.S. and internationally relating to Moderna’s unauthorized use of Arbutus/Genevant’s lipid nanoparticle (“LNP”) delivery technology in its vaccines, including Spikevax® (the “LNP Litigation”).","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1447028/000117184326001299/0001171843-26-001299-index.htm","comparable_excerpt":"On March 3, 2026 (the “Effective Date”), Moderna, Inc. (the “Company”) and ModernaTX, Inc. (together with the Company, “Moderna”) and Arbutus Biopharma Corporation (“Arbutus”), Genevant Sciences GmbH (“Genevant” and, together with Arbutus, “Arbutus/Genevant”), and, solely for certain purposes, Genevant Sciences Ltd., entered into a settlement agreement (the “Settlement Agreement”) to resolve all patent infringement litigation between Moderna and Arbutus/Genevant pending in the U.S. and internationally (the “Litigation”).","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1682852/000168285226000047/0001682852-26-000047-index.htm"}},{"accession":"0001193125-26-117652","ticker":"OESX","company_name":"ORION ENERGY SYSTEMS, INC.","filed_at":"2026-03-20T23:59:59+00:00","headline":"Orion settles Voltrek earnout dispute for $3M cash; solar PPA exit adds $1.3M offset","event_type":"litigation","sec_items":["1.01","8.01","9.01"],"materiality_score":0.75,"calibrated_materiality_score":0.75,"match_reasons":["same fact type: material_agreement","same SEC item: 1.01, 8.01, 9.01","same event type: litigation"],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-117652","json":"https://secwatch.observer/filing/0001193125-26-117652.json","markdown":"https://secwatch.observer/filing/0001193125-26-117652.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1409375/000119312526117652/0001193125-26-117652-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1409375/000119312526117652/oesx-20260317.htm"},"side_by_side_evidence":{"fact_type":"material_agreement","source_excerpt":"On March 3, 2026 (the “Effective Date”), Arbutus Biopharma Corporation (“Arbutus” or the “Company”), Genevant Sciences GmbH (“Genevant” and together with Arbutus, “Arbutus/Genevant”), and, solely for certain purposes, Genevant Sciences Ltd., and Moderna, Inc. and ModernaTx, Inc. (together, “Moderna”) entered into a settlement agreement (the “Settlement Agreement”) to resolve all patent infringement litigation between Arbutus/Genevant and Moderna pending in the U.S. and internationally relating to Moderna’s unauthorized use of Arbutus/Genevant’s lipid nanoparticle (“LNP”) delivery technology in its vaccines, including Spikevax® (the “LNP Litigation”).","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1447028/000117184326001299/0001171843-26-001299-index.htm","comparable_excerpt":"On March 17, 2026, Orion Energy Systems, Inc. and its subsidiaries (collectively, the “ Company ”) entered into a settlement agreement (the “ Settlement Agreement ”) with Final Frontier, LLC (“ Final Frontier ”) and Kathleen M. Connors (“ Ms. Connors ”), personally and as Trustee of the Kathleen M. Connors 2019 Revocable Trust","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1409375/000119312526117652/0001193125-26-117652-index.htm"}},{"accession":"0001437749-26-014906","ticker":"SGRP","company_name":"SPAR Group, Inc.","filed_at":"2026-05-05T23:59:59+00:00","headline":"SPAR Group settles arbitration with founder Robert Brown; extends CIC agreement to 2028","event_type":"litigation","sec_items":["1.01","9.01"],"materiality_score":0.65,"calibrated_materiality_score":0.65,"match_reasons":["same fact type: material_agreement","same SEC item: 1.01, 9.01","same event type: litigation"],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-26-014906","json":"https://secwatch.observer/filing/0001437749-26-014906.json","markdown":"https://secwatch.observer/filing/0001437749-26-014906.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1004989/000143774926014906/0001437749-26-014906-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1004989/000143774926014906/sgrp20260505_8k.htm"},"side_by_side_evidence":{"fact_type":"material_agreement","source_excerpt":"On March 3, 2026 (the “Effective Date”), Arbutus Biopharma Corporation (“Arbutus” or the “Company”), Genevant Sciences GmbH (“Genevant” and together with Arbutus, “Arbutus/Genevant”), and, solely for certain purposes, Genevant Sciences Ltd., and Moderna, Inc. and ModernaTx, Inc. (together, “Moderna”) entered into a settlement agreement (the “Settlement Agreement”) to resolve all patent infringement litigation between Arbutus/Genevant and Moderna pending in the U.S. and internationally relating to Moderna’s unauthorized use of Arbutus/Genevant’s lipid nanoparticle (“LNP”) delivery technology in its vaccines, including Spikevax® (the “LNP Litigation”).","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1447028/000117184326001299/0001171843-26-001299-index.htm","comparable_excerpt":"On May 1, 2026, the Company entered into a Settlement Agreement and Release with Robert G. Brown and SPAR Business Services, Inc. allowing for a dismissal of the Arbitration action between the Company and Robert G. Brown.","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1004989/000143774926014906/0001437749-26-014906-index.htm"}},{"accession":"0001805651-26-000038","ticker":"MKTW","company_name":"MARKETWISE, INC.","filed_at":"2026-04-24T23:59:59+00:00","headline":"MarketWise settles arbitration with former CEO for $12.16M cash, redeems 520,867 units, terminates TRA rights","event_type":"litigation","sec_items":["1.01","9.01"],"materiality_score":0.75,"calibrated_materiality_score":0.75,"match_reasons":["same fact type: material_agreement","same SEC item: 1.01, 9.01","same event type: litigation"],"urls":{"canonical":"https://secwatch.observer/filing/0001805651-26-000038","json":"https://secwatch.observer/filing/0001805651-26-000038.json","markdown":"https://secwatch.observer/filing/0001805651-26-000038.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1805651/000180565126000038/0001805651-26-000038-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1805651/000180565126000038/mktw-20260421.htm"},"side_by_side_evidence":{"fact_type":"material_agreement","source_excerpt":"On March 3, 2026 (the “Effective Date”), Arbutus Biopharma Corporation (“Arbutus” or the “Company”), Genevant Sciences GmbH (“Genevant” and together with Arbutus, “Arbutus/Genevant”), and, solely for certain purposes, Genevant Sciences Ltd., and Moderna, Inc. and ModernaTx, Inc. (together, “Moderna”) entered into a settlement agreement (the “Settlement Agreement”) to resolve all patent infringement litigation between Arbutus/Genevant and Moderna pending in the U.S. and internationally relating to Moderna’s unauthorized use of Arbutus/Genevant’s lipid nanoparticle (“LNP”) delivery technology in its vaccines, including Spikevax® (the “LNP Litigation”).","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1447028/000117184326001299/0001171843-26-001299-index.htm","comparable_excerpt":"On April 21, 2026, Marketwise, Inc. (the “Company”) and its subsidiary, MarketWise, LLC (together with the Company, “MarketWise”), entered into a Settlement Agreement and Release (the “Settlement Agreement”) with Mark P. Arnold, the Company’s former Chief Executive Officer, and JAMA 2021, LLC (together with Mr. Arnold, the “Arnold Parties”).","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1805651/000180565126000038/0001805651-26-000038-index.htm"}}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}